New drug combo aims to shrink Hard-to-Treat head and neck tumors
Disease control
Ongoing
This phase 2 trial tests two different doses of a nano-encapsulated chemotherapy drug called FID-007, combined with cetuximab, in 46 people with advanced head and neck cancer that has returned or spread. The goal is to see how well the combination shrinks tumors and to check for …
Phase: PHASE2 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC